Cargando…

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2

SIMPLE SUMMARY: Drug resistance is the main cause of sorafenib treatment failure in clinical acute myeloid leukemia (AML) patients, but the mechanism is currently not fully clear. In this study, we analyzed the genetic characteristics of sorafenib-resistant AML cell subclusters using single-cell and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xi, Ma, Weiwei, Qiu, Guo, Xuan, Li, He, Chong, Zhang, Tian, Wang, Jian, Liu, Qifa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603903/ https://www.ncbi.nlm.nih.gov/pubmed/37887047 http://dx.doi.org/10.3390/biology12101337

Ejemplares similares

An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia
por: Przedborski, Michelle, et al.
Publicado: (2022)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
por: Han, Lina, et al.
Publicado: (2020)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
por: Zhang, Xiang, et al.
Publicado: (2021)

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
por: Avsec, Damjan, et al.
Publicado: (2022)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
por: Garg, Ravendra, et al.
Publicado: (2020)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
por: Vänttinen, Ida, et al.
Publicado: (2023)

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
por: Nishida, Yuki, et al.
Publicado: (2023)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
por: Griffioen, Mila S., et al.
Publicado: (2022)

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
por: Wang, Bin-Ru, et al.
Publicado: (2021)

AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia
por: Legrand, Noémie, et al.
Publicado: (2021)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2022)

P469: ACUTE MYELOID LEUKEMIA DRIVES BCL-2 UPREGULATION IN NON MALIGNANT HSPCS WHICH IS TARGETED BY VENETOCLAX AND CAUSES CYTOPENIA
por: Fowler-Shorten, Dominic, et al.
Publicado: (2023)

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
por: Lewis, Alexander C., et al.
Publicado: (2022)

Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2022)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance
por: Garciaz, Sylvain, et al.
Publicado: (2021)

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance
por: Åbacka, Hannah, et al.
Publicado: (2021)

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia
por: Sharma, Priyanka, et al.
Publicado: (2023)

DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax
por: Ye, Sisi, et al.
Publicado: (2023)

Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells
por: Zhou, Weihua, et al.
Publicado: (2015)

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
por: Chyla, Brenda, et al.
Publicado: (2018)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome
por: Houshmand, Mohammad, et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
por: Buettner, Ralf, et al.
Publicado: (2021)

A novel polyethylene glycol (PEG)‐drug conjugate of Venetoclax, a Bcl‐2 inhibitor, for treatment of acute myeloid leukemia (AML)
por: Ando, Hidenori, et al.
Publicado: (2021)

P408: COMBINATORIAL BCL-2 FAMILY EXPRESSION IN ACUTE MYELOID LEUKEMIA STEM CELLS PREDICTS CLINICAL RESPONSE TO AZACITIDINE/VENETOCLAX
por: Renders, Simon, et al.
Publicado: (2023)

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2018)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

Targeting of the leukemia microenvironment by c(RGDfV) overcomes the resistance to chemotherapy in acute myeloid leukemia in biomimetic polystyrene scaffolds
por: Shen, Zhao-Hua, et al.
Publicado: (2016)

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
por: Waggoner, Matthew, et al.
Publicado: (2022)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
por: Knight, Tristan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ekdff4stgte8al10eebote3c75